PRISM BioLab Co.,LTD (TYO:206A)

Revenue by Segment

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023
Drug Discovery Business	677.33M	305.62M	112.93M
Drug Discovery Business Growth	121.62%	170.64%	-
Total	677.33M	305.62M	112.93M
Total Growth	121.62%	170.64%	-

Revenue by Geography

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023
Japan	110.00M	69.63M	68.04M
Japan Growth	57.98%	2.34%	-
United States of America	523.50M	219.20M	11.78M
United States of America Growth	138.82%	1761.56%	-
Switzerland	43.83M	16.79M	12.06M
Switzerland Growth	161.00%	39.24%	-
France	-	-	21.05M
Total	677.33M	305.62M	112.93M
Total Growth	121.62%	170.64%	-

Source: S&P Global Market Intelligence.